Abstract: The present disclosure discloses the chemical synthesis method of the Plesiomonas shigelloides serotype O51 O-antigen oligosaccharide, belonging to the field of chemistry. Source-abundant D-glucose, L-fucose, D-glucosamine and the like are used as raw materials to prepare three glycosylation building blocks, the synthetic route composed of 11 reaction modules is designed, and through the optimization of protecting group and the optimization of the time of introducing functional group, the preparation of the target oligosaccharide chain is successfully achieved. The oligosaccharide chain prepared in the present disclosure has the advantages of cheap and easy-to-get raw materials, and simple and easy-to-repeat preparation method. The present disclosure will have good application prospects in the aspects of development of new drugs and vaccines of Plesiomonas shigelloides, and the like.

Abstract: The present invention relates to a process for obtaining polysaccharides from jatoba seeds, comprising the steps of: a) seed processing (dry process); b) aqueous extraction at 1% to 5% of powder mass per volume, preferably 2% of powder mass per volume; c) precipitation with ethanol 969GL using 1 to 3 times the aqueous extract volume; d) press filtration of the precipitate obtained in (c); e) solublization of the polysaccharides obtained in step (d) with water; and f) drying the polysaccharides obtained in step (e). In another embodiment, the present invention relates to a cosmetic composition containing polysaccharides obtained according to the process defined above and to the use of said polysaccharides.

Abstract: Provided is a means for preventing the inactivation of a photoresponsive nucleic acid probe by suppressing the formation of a photocrosslink between a modified nucleotide having a structure corresponding to the monomer of Formula (II) or an amino acid analogue of a nucleotide having a structure corresponding to the monomer of Formula (III) and a modified nucleotide having a structure corresponding to the monomer of Formula (I), wherein the modified nucleotide replaces at least one constituent nucleotide which is the photocrosslinkable 1-thyminyl or 1-uracilyl, by substituting at least one constituent nucleotide which is the photocrosslinkable 1-thyminyl or 1-uracilyl with a modified nucleotide having a structure corresponding to the monomer of Formula (I).

Abstract: Products and processes that are related to phosphonated polysaccharide compositions, including phosphonated polysaccharide gels, having a substituent degree of substitution with a lower limit of 0.02 and an upper limit of 3, and having a weight average molecular weight with an upper limit of 5,000,000 g/mole, as well as to oil field application or fracturing fluid compositions comprising such phosphonated polysaccharide compositions.

Abstract: A synthetic composition for use in improving one or more co-morbid mental disorder symptoms of a patient with IBS, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.

Abstract: In certain embodiments APP-specific BACE inhibitors (ASBIs) are provided as well as uses thereof. In certain embodiments methods of preventing delaying the onset of a pre-Alzheimer's condition and/or cognitive dysfunction, and/or ameliorating one or more symptoms of a pre-Alzheimer's condition and/or cognitive dysfunction, or preventing or delaying the progression of a pre-Alzheimer's condition or cognitive dysfunction to Alzheimer's disease are provided where the method involves administering to a subject in need thereof an APP specific BACE inhibitor (ASBI) in an amount sufficient to prevent or delay the onset of a pre-Alzheimer's cognitive dysfunction, and/or to ameliorate one or more symptoms of a pre-Alzheimer's cognitive dysfunction, and/or to prevent or delay the progression of a pre-Alzheimer's cognitive dysfunction to Alzheimer's disease. In certain embodiments the ASBI is a flavonoid (e.g. galangin) or flavonoid progrug (e.g., galangin prodrug).

Abstract: Combination therapies for treatment of cancer are provided. The disclosed methods comprise administration of a cyclin-dependent kinase inhibitor and a DNA methyltransferase inhibitor to a mammal in need thereof.

Abstract: The application relates to synthetic compositions containing one or more human milk oligosaccharides for regulating satiety or reducing propensity to obesity.

Abstract: The invention relates to a synthetic composition comprising one or more human milk monosaccharides and/or one or more human milk oligosaccharides for use in reducing intestinal permeability, endotoxemia and/or low-grade inflammation in patients with metabolic disorders.

Abstract: The present invention relates to a nutritional composition comprising at least one fucosylated oligosaccharide for use in preventing and/or treating constipation and/or in improving stool consistency/frequency in an infant or a young child.

Abstract: A nutritional composition contains Fut2-dependent oligosaccharides for promoting brain growth and development in infants in the very early postnatal period. The nutritional composition contains Fut2-dependent oligosaccharides and Lacto-N-neotetraose and is specifically for use in promoting brain catch-up growth in preterm infants or infants with low-birth weight. A kit can include at least two of these nutritional compositions.

Abstract: The present invention relates to pharmaceutical formulations containing a combination of specific high-molecular weight hyaluronic acid derivatives and chondroitin sulfate to be used in the treatment of osteoarthritis, of subchondral damage, osteoporosis, synovitis, tenosynovitis, tendinitis, tendinosis, as an intra-articular washing liquid and as a viscous substitute of synovial fluid following osteochondral surgery. These formulations are also suitable for the treatment of interstitial cystitis.

Abstract: The invention relates to substituted cyclodextrins and pharmaceutically acceptable salts thereof, pharmaceutical compositions, kits of parts and their use as procoagulants. The invention further relates to methods of reversing an anticoagulant effect of an anticoagulant in a subject, methods for reducing or preventing bleeding in a subject and methods for the treatment or prevention of a blood coagulation disorder.

Abstract: Glycosylated Antitumor Ether Lipids (GAELs) kill cancer cells by a nonapoptotic pathway which is an attractive strategy to avoid resistance. To further optimize the antitumor effect, we prepared various analogs of di-, and tri-cationic GAEL analogs differing in the nature of the sugar (D-glucose or L-glucose), the anomeric linkage as well as position of the glycerolipid moiety. The di- and tri-cationic GAELs were synthesized and their in vitro anticancer properties were evaluated against drug resistant and aggressively growing cancer cell lines derived from human breast, prostate, pancreatic and ovarian cancers. The most potent dicationic GAEL analogs were also studied against cancer stem cells obtained from breast BT 474, prostate DU145 and ovarian A2780cp cell lines. Our results indicate that the number of positive charges, the position of the amino substituents and the nature of the sugar have significant effects on the anticancer activities of these compounds.

Abstract: The present invention related to low-chloride alkylated cyclodextrin compositions, along with processes for preparing and using the same. The processes of the present invention provide alkylated cyclodextrins with low levels of drug-degrading agents and chloride.

Abstract: A polymeric blend composition comprising: (a) from about 1 to about 99 wt. % of a polymer; and (b) from about 1 to about 75 wt. % poly alpha-1,3-glucan is disclosed. The addition of alpha-1,3-glucan as a polymer filler can increase the tensile modulus, tensile strength and oxygen barrier properties of the polymeric blend composition.

Abstract: Provided are methods of treating urothelial carcinomas of the lower tract comprising administering comprising administering gemcitabine continuously and locally to the bladder of an individual in an induction therapy and/or maintenance therapy.

Abstract: A polysaccharide derivative has a partial structure represented by Formula (1) below. It is preferable that at least one of the amino acids that constitute X2 in Formula (1) below is a basic amino acid. (In the formula, X1 represents a residue obtained by removing the terminal amino group and the terminal carboxyl group from a neutral amino acid or an ?-aminoalkanoic acid, X2 represents a residue obtained by removing the terminal amino group and the terminal carboxyl group from a membrane-permeable peptide, X3 represents a hydroxyl group, an amino group, an alkoxyl group having 1 to 4 carbon atoms, or a benzyloxy group, a represents a number of 0 or 1, and b represents a number of from 0 to 50.

Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

Abstract: The present disclosure relates to treatment of a pulmonary disease. The methods and kits provided herein facilitate relieving the symptoms resulting from the pulmonary disease (e.g., asthma, chronic obstructive pulmonary disease (COPD), etc.).